On January 26, 2016, a motion for miscellaneous “first day” relief was filed in the bankruptcy case of Nuo Therapeutics, Inc. (f/k/a Cytomedix, Inc.) and its affiliates.
The filing was assigned docket number 12 and is described on the court’s official docket as follows:
Motion Regarding Chapter 11 First Day Motions // Debtor’s Motion Pursuant to Sections 105(a), 362(d), 363(b), 363(c) And 503(b) of the Bankruptcy Code (I) for Authorization to (A) Continue Its Workers’ Compensation, Liability, Property, and Other Insurance Programs, (B) Pay All Obligations In Respect Thereof and (C) Enter Into Premium Financing Agreements in the Ordinary Course of Business, and (II) for Authorization for Financial Institutions to Honor and Process Checks and Transfers Related to Such Obligations Filed By Nuo Therapeutics, Inc. (Skomorucha Owens, Karen) (Entered: 01/26/2016)
Nuo Therapeutics, Inc. (f/k/a Cytomedix, Inc.) filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on January 26, 2016. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Delaware. The case number for the lead bankruptcy case is 16-10192. The bankruptcy case is currently assigned to United States Bankruptcy Judge Mary Walrath. The law firm of Dentons US LLP is acting as lead bankruptcy counsel to Nuo Therapeutics, Inc. (f/k/a Cytomedix, Inc.) in the bankruptcy case.